201 related articles for article (PubMed ID: 6708049)
1. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.
Zon G; Ludeman SM; Brandt JA; Boyd VL; Ozkan G; Egan W; Shao KL
J Med Chem; 1984 Apr; 27(4):466-85. PubMed ID: 6708049
[TBL] [Abstract][Full Text] [Related]
2. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution.
Borch RF; Hoye TR; Swanson TA
J Med Chem; 1984 Apr; 27(4):490-4. PubMed ID: 6708051
[TBL] [Abstract][Full Text] [Related]
3. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
4. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of activation of 4-hydroxycyclophosphamide.
Borch RF; Millard JA
J Med Chem; 1987 Feb; 30(2):427-31. PubMed ID: 3806624
[TBL] [Abstract][Full Text] [Related]
6. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
[TBL] [Abstract][Full Text] [Related]
7. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species.
Boyd VL; Summers MF; Ludeman SM; Egan W; Zon G; Regan JB
J Med Chem; 1987 Feb; 30(2):366-74. PubMed ID: 3806617
[TBL] [Abstract][Full Text] [Related]
8. The chemistry of the metabolites of cyclophosphamide.
Ludeman SM
Curr Pharm Des; 1999 Aug; 5(8):627-43. PubMed ID: 10469895
[TBL] [Abstract][Full Text] [Related]
9. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites.
Boyd VL; Robbins JD; Egan W; Ludeman SM
J Med Chem; 1986 Jul; 29(7):1206-10. PubMed ID: 3543359
[TBL] [Abstract][Full Text] [Related]
10. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy.
Dirven HA; Venekamp JC; van Ommen B; van Bladeren PJ
Chem Biol Interact; 1994 Dec; 93(3):185-96. PubMed ID: 7923439
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.
Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
J Med Chem; 1986 May; 29(5):716-27. PubMed ID: 3701785
[TBL] [Abstract][Full Text] [Related]
12. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
13. Effect of stereochemistry on the oxidative metabolism of the cyclophosphamide metabolite aldophosphamide.
Habib AD; Boal JH; Hilton J; Nguyen T; Chang YH; Ludeman SM
Biochem Pharmacol; 1995 Jul; 50(3):429-33. PubMed ID: 7646546
[TBL] [Abstract][Full Text] [Related]
14. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: synthesis and deuterium labeling for applications to metabolite quantification.
Ludeman SM; Shulman-Roskes EM; Wong KK; Han SY; Anderson LW; Strong JM; Colvin OM
J Pharm Sci; 1995 Apr; 84(4):393-8. PubMed ID: 7629726
[TBL] [Abstract][Full Text] [Related]
15. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.
Manthey CL; Sladek NE
Biochem Pharmacol; 1988 Jul; 37(14):2781-90. PubMed ID: 3395357
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.
Belfayol-Pisanté L; Guillevin L; Tod M; Fauvelle F
Fundam Clin Pharmacol; 2000; 14(4):415-21. PubMed ID: 11030450
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
18. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide.
Parekh HK; Sladek NE
Biochem Pharmacol; 1993 Sep; 46(6):1043-52. PubMed ID: 8216347
[TBL] [Abstract][Full Text] [Related]
19. 5-Fluoro- and 5-chlorocyclophosphamide: synthesis, metabolism, and antitumor activity of the cis and trans isomers.
Foster AB; Jarman M; Kinas RW; van Maanen JM; Taylor GN; Gaston JL; Parkin A; Richardson AC
J Med Chem; 1981 Dec; 24(12):1399-403. PubMed ID: 7310816
[TBL] [Abstract][Full Text] [Related]
20. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
